Jared S. Hopkins
Pharma Reporter at The Wall Street Journal
Pharma for @WSJ but I also once interviewed John Oates. [email protected] https://t.co/pMHJnBKbFF
Articles
-
2 days ago |
cn.wsj.com | Jared S. Hopkins
莫德纳(Moderna)曾是特朗普(Trump)第一届政府的宠儿，当时政府不遗余力地帮助这家公司开发新冠疫苗，保护了上亿民众免受该病毒侵害。如今，随着疫苗生产受到抨击，这家生物技术公司成为了特朗普2.0的靶子。莫德纳遭遇的最新挫折是，美国食品药品管理局(Food and Drug Administration, 简称FDA)上周五批准了其下一代新冠疫苗，但适用人群范围比该公司预期的要窄。此次批准仅授权该疫苗用于老年人以及年龄在12至64岁之间有健康风险的人群。Copyright ©2025 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
-
3 days ago |
jp.wsj.com | Jared S. Hopkins |Peter Loftus
モデルナは第1次トランプ政権でコロナワクチンが称賛されたが、現在はワクチン規制の変更で逆風に直面 米バイオ医薬品会社モデルナは第1次トランプ政権における寵児（ちょうじ）だった。政府は同社による新型コロナウイルスワクチンの開発を全面的に支援し、開発されたワクチンは多くの人々をウイルスから守った。だが現在、ワクチン製造全体への逆風が強まり、モデルナは第2次トランプ政権の標的となっている。 米食品医薬品局（FDA）の動きはモデルナにとって新たな打撃となった。FDAは5月30日、モデルナの次世代コロナワクチンを承認した。ただ、接種対象は高齢者と健康上のリスクがある12～64歳に限定され、患者層は同社が意図していたよりも狭いものとなった。Copyright ©2025 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8ウォール・ストリート・ジャーナル日本版今すぐ購読する
-
3 days ago |
wsj.com | Jared S. Hopkins |Peter Loftus
The biotech’s mRNA vaccines were lauded by the first Trump administration but now are caught up in government changes to vaccine rulesIn the latest setback for Moderna, the Food and Drug Administration on Friday approved its next-generation Covid shot for a narrower population of patients than the company intended. The approval grants use of the vaccine only in older adults and people aged 12 to 64 with health risks. Copyright ©2025 Dow Jones & Company, Inc. All Rights Reserved.
-
3 days ago |
livemint.com | Jared S. Hopkins |Peter Loftus
Global Summary The biotech’s mRNA vaccines were lauded by the first Trump administration but now are caught up in government changes to vaccine rules. This is a Mint Premium article gifted to you. Subscribe to enjoy similar stories. The Trump administration is seeking to reshape the regulation, recommendations and development of vaccines.
-
1 week ago |
wsj.com | Jared S. Hopkins
Bristol-Myers Squibb Chief Executive Chris Boerner said at The Wall Street Journal's Future of Everything festival on Thursday that potential tariffs targeting the drug industry from the Trump administration must not create supply constraints. Bristol and other drugmakers are bracing for tariffs targeting pharmaceuticals shipped to the U.S. from other countries. The administration has been conducting an investigation into such levies, and analysts expect them to be announced in coming weeks.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 6K
- Tweets
- 17K
- DMs Open
- Yes
Scoop: Drugmaker Mallinckrodt is talking to hedge funds that lent it money about a plan to file for bankruptcy and avoid paying $1 billion it owes to opioid victims https://t.co/FoczV33AER via @gladstonea @ajsaeedy
RT @eliotwb: 17 Weeks. I took a turn at writing some about Evan in today's print WSJ page devoted to him. check it out here Free Evan.…
Here is a link for the next 24 hours of @WSJ reporter Evan Gershkovich’s colleagues, family and friends reading his journalism - please tune in often to discover his work and share with the world #IStandWithEvan https://t.co/I6n9O5u1TS
